These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23056335)

  • 1. Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study.
    Sandberg ME; Hall P; Hartman M; Johansson AL; Eloranta S; Ploner A; Czene K
    PLoS One; 2012; 7(10):e46535. PubMed ID: 23056335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
    Mezencev R; Švajdler M
    Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
    Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
    Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
    Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype.
    Kramer I; Schaapveld M; Oldenburg HSA; Sonke GS; McCool D; van Leeuwen FE; Van de Vijver KK; Russell NS; Linn SC; Siesling S; Menke-van der Houven van Oordt CW; Schmidt MK
    J Natl Cancer Inst; 2019 Jul; 111(7):709-718. PubMed ID: 30698719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
    Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
    Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
    Rusner C; Wolf K; Bandemer-Greulich U; Engel J; Stegmaier C; Holleczek B; Schubert-Fritschle G; Tillack A; Stang A
    Breast Cancer Res; 2014 Oct; 16(5):452. PubMed ID: 25277819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for contralateral breast cancer in Chennai (Madras), India.
    Gajalakshmi CK; Shanta V; Hakama M
    Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of second breast cancer according to estrogen receptor status and family history.
    Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
    Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
    Nichols HB; Berrington de González A; Lacey JV; Rosenberg PS; Anderson WF
    J Clin Oncol; 2011 Apr; 29(12):1564-9. PubMed ID: 21402610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
    Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
    JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands.
    Schaapveld M; Visser O; Louwman WJ; Willemse PH; de Vries EG; van der Graaf WT; Otter R; Coebergh JW; van Leeuwen FE
    Breast Cancer Res Treat; 2008 Jul; 110(1):189-97. PubMed ID: 17687645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
    Alkner S; Bendahl PO; Ehinger A; Lövgren K; Rydén L; Fernö M
    PLoS One; 2016; 11(3):e0150977. PubMed ID: 26959415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
    Neta G; Anderson WF; Gilbert E; Berrington A
    Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and risk of second primary breast cancer: the WECARE Study.
    Brooks JD; John EM; Mellemkjær L; Reiner AS; Malone KE; Lynch CF; Figueiredo JC; Haile RW; Shore RE; ; Bernstein JL; Bernstein L
    Breast Cancer Res Treat; 2012 Jan; 131(2):571-80. PubMed ID: 21892703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.